(Q51990374)

19 April 2018

MDMA

0 references

title

MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. (English)

1 reference

19 April 2018

0 references

Schifano F

1

1 reference

19 April 2018

Di Furia L

2

1 reference

19 April 2018

Forza G

3

1 reference

19 April 2018

Minicuci N

4

1 reference

19 April 2018

Bricolo R

5

1 reference

19 April 2018

publication date

1 September 1998

1 reference

19 April 2018

Drug and Alcohol Dependence

published in

1 reference

19 April 2018

volume

52

1 reference

19 April 2018

page(s)

85-90

1 reference

19 April 2018

issue

1

1 reference

19 April 2018

Ecstasy and neurodegeneration

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Ecstasy and the dance of death

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

MDMA (Ecstasy) precipitation of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Specific impairments of planning

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Chronic atypical psychosis associated with MDMA ("ecstasy") abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

MDMA ("ecstasy") abuse: psychopathological features and craving for chocolate: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Ecstasy (3,4-methylenedioxymethamphetamine)

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900051-9

7 January 2021

10.1016/S0376-8716(98)00051-9

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

9788011

1 reference

19 April 2018